Integrated clinical, genomic and functional characterization of a novel ALK variant in neuroblastoma

  • Cancer Lett. 2026 May 29:656:218624. doi: 10.1016/j.canlet.2026.218624.
Ana Cañadas García  1 ,  Ketan Thombare  2 ,  Leila Jahangiri  1 ,  Alisha R Burman  1 ,  Stephen P Ducray  1 ,  G A Amos Burke  3 ,  Angharad Goodman  4 ,  Emma R Woodward  5 ,  Edmund Cheesman  5 ,  Anthony Penn  5 ,  Tanmoy Mondal  2 ,  Suzanne D Turner  6 ,  Perla Pucci  7
Affiliations
  • 1. Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, CB20QQ, UK.
  • 2. Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Sweden; Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.
  • 3. CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • 4. Newcastle Genetics Laboratory, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, UK.
  • 5. Department of Paediatric Oncology, Royal Manchester Children's Hospital, Division of Cancer Sciences, University of Manchester & Manchester Centre for Genomic Medicine, Manchester, M13 9WL, UK.
  • 6. Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, CB20QQ, UK; European Research Initiative for ALK Related Malignancies (ERIA), UK; Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: [email protected].
  • 7. Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, CB20QQ, UK. Electronic address: [email protected].
PMID: 42217560 DOI: 10.1016/j.canlet.2026.218624
Products